Postgraduate Healthcare Education - PowerPak’s Post

Live Webinar – Acne Vulgaris Therapeutic Update: Overview of the 2024 Treatment Guidelines on May 30th.  Over 50 million people in the US have acne, leading to $846 million in medical costs and $398 million in lost productivity. This live webinar will review acne vulgaris and its clinical features along with summarizing the 2024 American Academy of Dermatology Guidelines for this condition. Learn More - https://bit.ly/3JHDto4 FACULTY - Darrell Hulisz, RPh, PharmD

Latest living network meta-analysis (NMA) update published in JAMA Dermatology! We are delighted to share the results of our NMA, this time focused on lebrikizumab and how it compares to other systemic treatments for atopic dermatitis. Do check out our open access paper here: https://lnkd.in/gJEW39TY JAMA Dermatol. doi:10.1001/jamadermatol.2024.2192 Carsten Flohr and Aaron Drucker

Experts in dermatology provide a comprehensive year in review regarding the management of plaque psoriasis, highlighting key therapeutic approvals from 2023. The discussion will highlight pivotal clinical studies supporting these approvals and our discussion will then pivot to have a special focus on addressing the unique challenges faced by treating patients with skin of color and treatment access barriers. Explore the series here: https://ow.ly/az7y50RSCnx

Our depth of expertise ensures precision and innovation in every dermatological study we undertake. We manage global Phase II-III trials in conjunction with our standalone Phase I unit. Trust TKL Research for a journey of excellence in dermatology research. #TKLResearch #DermatologyExpertise #ClinicalInnovation

Learn from dermatology experts as they provide a comprehensive year in review regarding the management of plaque psoriasis and highlight key therapeutic approvals from 2023. Explore the DermView series here: https://ow.ly/8skA50Rwn3O

Just published in Dermatology and Therapy!! “Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis” I’m happy to share our last publication (with Anne Sohrt Petersen, Ulla Ivens, PhD, Albert Bosch Vilaró, John Stinson and Jose Manuel Carrascosa Carrillo), where we conducted a matching adjusted indirect comparison of the efficacy at week 32 of tralokinumab and dupilumab in combination with topical corticosteroids (TCS). The results of this analysis showed that tralokinumab and dupilumab, both in combination with TCS, have similar efficacy at 32 weeks. Full paper: https://lnkd.in/d7t4XVEY #atopicdermatitis #biologictherapy

Just attended an enlightening learning activity provided by ASHP on JAK Inhibitors and the Changing Landscape of Atopic Dermatitis and Alopecia Areata Management. The activity presented and analyzed the safety and efficacy data of JAK inhibitors in different populations, and it was truly eye-opening. 💡Here are some key takeaways: - Atopic dermatitis and alopecia areata are two challenging conditions that significantly impact the lives of patients. - The emergence of JAK inhibitors has brought new hope to the field of dermatology. - Black box warnings include an increased risk for MACE with JAK inhibitors. - Pharmacists’ role include proper counseling of the use of JAK inhibitors and their potential adverse effects as well as management of adverse effects.

Check out The Journal of Clinical and Aesthetic Dermatology's newest release of Hot Topics with updates in Psoriasis, featuring a literature review of treatment efficacy and dosing in patients on UCB's bimekizumab and how this can improve patient adherence and satisfaction!

If you're participating in the Advancing Innovation in Dermatology, Inc. Summit and want to discover how Alpenglow Biosciences' 3D Derm Score™ Assay can expedite the advancement of novel therapeutics and diagnostic approaches for skin diseases, contact Nicholas Reder. Schedule a meeting with him using this link: https://lnkd.in/guKh2wKt. #spatialbiology #ai #ml #image #3dimaging #reserach #3Dspatialbiology #alpenglowbiosciences #3d #imaging #tissues #pathology #research #spatialanalysis #clinical #translationalresearch #digital #digitalpathology

Today we presented positive data from a Phase 2 clinical trial of ESK-001, a highly selective allosteric TYK2 inhibitor, for the treatment of plaque #psoriasis at the American Academy of Dermatology Annual Meeting. Learn more: https://lnkd.in/e9pKPCBM #AAD2024